|
 U.S. federal health agencies recommended on Tuesday that use of a
similar one-shot vaccine from Johnson & Johnson be paused after six
women developed rare blood clots.
CanSinoBIO's shares fell as much as 13.7% and 18.4% in Shanghai and
Hong Kong respectively.
They pared losses to close down 6.3% and 7.7% each after the company
issued a statement in which it said: "No blood clot related serious
adverse events have been reported in around one million vaccinations
of Ad5-nCoV."
CanSinoBIO's Ad5-nCoV vaccine is approved in China, Hungary, Chile
and Pakistan.
European regulators this month said they had found a possible link
between AstraZeneca Plc's vaccine and a similar rare blood clotting
problem.
Several countries have since limited the AstraZeneca vaccine's use
to certain age groups, while the European Medicines Agency (EMA)
said the benefits outweigh the risks.
Experts said clotting risks for both vaccines remain extremely low
and they are highly effective in providing protection against
COVID-19, amid concern that reports of the rare side effects could
deter people from getting their shots.
[to top of second column] |
"There are other vaccines in clinical use where rare side effects
are reported – rotavirus, measles, yellow fever. Yet the vaccines
save hundreds of thousands of lives," said Jerome Kim, director
general of the International Vaccine Institute.
"We are looking at rare events ... Countries need to assess the risk
of vaccination against the known risk of not vaccinating."
COVID-19 vaccines from J&J, AstraZeneca, CanSinoBIO and Russia's
Gamaleya Institute uses an adenovirus, a harmless cold virus, as a
vector to deliver instructions for human cells to produce part of
the coronavirus that can spur the immune system to recognise and
attack the actual virus.
(Reporting by Roxanne Liu and Ryan Woo in Beijing, Shashwat Awasthi
in Bengaluru; Editing by Miyoung Kim and Jason Neely)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
 |
